| Autor: |
Basil Kaufmann, Sharon Fischer, Alcibiade Athanasiou, Noémie Lautenbach, Anja Wittig, Uwe Bieri, Florian A. Schmid, Franz vonStauffenberg, Thomas Scherer, Daniel Eberli, Michael A. Gorin, Ralph Schiess, Cédric Poyet |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BJUI Compass, Vol 5, Iss 2, Pp 297-303 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2688-4526 |
| DOI: |
10.1002/bco2.293 |
| Popis: |
Abstract Objectives The use of multiparametric magnetic resonance imaging (mpMRI) has been widely adopted in the diagnostic work‐up for suspicious prostate cancer (PCa) and is recommended in most current guidelines. However, mpMRI lesions are often indeterminate and/or turn out to be false‐positive on prostate biopsy. The aim of this work was to evaluate Proclarix, a biomarker test for the detection of relevant PCa, regarding its diagnostic value in all men before biopsy and in men with indeterminate lesions on mpMRI (PI‐RADS 3) during work‐up for PCa. Materials and Methods Men undergoing mpMRI‐targeted and systematic biopsy of the prostate were prospectively enrolled. The Proclarix test was evaluated for the detection accuracy of clinically significant PCa (csPCa) defined as Grade Group ≥ 2 and its association to mpMRI results. Further, Proclarix's performance was also tested when adapted to prostate volume (Proclarix density) and performance compared to PSA density (PSAD). Results A total of 150 men with a median age of 65 years and median PSA of 5.8 ng/mL were included in this study. CsPCa was diagnosed in 65 (43%) men. Proclarix was significantly associated with csPCa and higher PI‐RADS score (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text